At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 116 enrolled
Drug / intervention
SHJ002 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Study on the Safety and Efficacy of SHJ002 Sterile Ophthalmic Solution in the Treatment of Corneal Erosion in Patients With Sjogren's Syndrome
In Brief
A Phase 2 clinical trial evaluating SHJ002 and Vehicle for Corneal Erosion. Completed, enrolled 116 participants across 6 sites.
Detailed Summary
The purpose of this study is to measure efficacy and safety with 0.25% SHJ002 sterile ophthalmic solution compared to vehicle in treating corneal erosion in Sjogren's patients. SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorneal Erosion
CountriesTaiwan
Collaborators--
Timeline
Phase 2CompletedFinished
20252026
First PostedApr 2024
Enrollment StartJun 2024
Primary CompletionApr 2025
Study CompletionApr 2025
TodayJul 2026
First PostedApr 24, 2024
Enrollment StartJun 28, 2024
Primary CompletionApr 10, 2025
Study CompletionApr 17, 2025
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 2.2 years ago
Interventions
SHJ002drug
Topical ophthalmic
Vehicleother
Topical ophthalmic